(LPTN) - Earnings & Price History

LPTN: - 2.93, $0.00M, -2.93 (-100.00%)

Sector: Healthcare - Industry: Biotechnology

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States. It develops Lpathomab, a humanized monoclonal antibody (mAb) against lysophosphatidic acid that has completed Phase 1a clinical trial for various chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain, and pain associated with lumbosacral radiculopathy. The company also develops iSONEP, a mAb against sphingosine-1-phosphate, which is in Phase II clinical trial for the treatment of wet age-related macular degeneration; and ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid sphingosine-1-phosphate (S1P), which is in Phase IIa clinical trial to treat kidney cancer, leukemia, prostate cancer, neuroblastoma, lu

Past LPTN reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades